Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Tissue Res ; 391(3): 523-544, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36543895

ABSTRACT

Tendon injuries occur commonly in both human and equine athletes, and poor tendon regeneration leads to functionally deficient scar tissue and an increased frequency of re-injury. Despite evidence suggesting inadequate resolution of inflammation leads to fibrotic healing, our understanding of the inflammatory pathways implicated in tendinopathy remains poorly understood, meaning successful targeted treatments are lacking. Here, we demonstrate IL-1ß, TNFα and IFN-γ work synergistically to induce greater detrimental consequences for equine tenocytes than when used individually. This includes altering tendon associated and matrix metalloproteinase gene expression and impairing the cells' ability to contract a 3-D collagen gel, a culture technique which more closely resembles the in vivo environment. Moreover, these adverse effects cannot be rescued by direct suppression of IL-1ß using IL-1RA or factors produced by BM-MSCs. Furthermore, we provide evidence that NF-κB, but not JNK, P38 MAPK or STAT 1, is translocated to the nucleus and able to bind to DNA in tenocytes following TNFα and IL-1ß stimulation, suggesting this signalling cascade may be responsible for the adverse downstream consequences of these inflammatory cytokines. We suggest a superior approach for treatment of tendinopathy may therefore be to target specific signalling pathways such as NF-κB.


Subject(s)
Mesenchymal Stem Cells , Tendinopathy , Humans , Animals , Horses , Tumor Necrosis Factor-alpha/metabolism , Interleukin-1beta/metabolism , NF-kappa B/metabolism , Interleukin 1 Receptor Antagonist Protein/genetics , Interleukin 1 Receptor Antagonist Protein/metabolism , Interferon-gamma/metabolism , Tenocytes/metabolism , Tendinopathy/metabolism , Cells, Cultured
2.
Stem Cells Dev ; 29(7): 425-439, 2020 04 01.
Article in English | MEDLINE | ID: mdl-31973649

ABSTRACT

The objective of this study was to determine whether corneal stromal cells (CSCs) from the limbal and central corneal stroma in dogs have multipotent mesenchymal stem/stromal cell (MSC) properties, and whether this cell population can be differentiated into keratocyte-like cells (KDCs). Normal, donated, mesocephalic dog corneas were used to isolate CSC in vitro. Immunohistochemistry demonstrated a distinct population of CD90 expressing cells in the anterior stroma throughout the limbal and central cornea. CSC could be cultured from both the limbal and central cornea and the culture kinetics showed a progenitor cell profile. The CSC expressed stem cell markers CD90, CD73, CD105, N-cadherin, and Pax6, while CD34 was negative. Limbal and central CSC differentiated into osteoblasts, chondrocytes, and adipocytes confirming their multipotency. Coculturing allogeneic peripheral blood mononuclear cells (PBMCs) with limbal CSCs did not affect baseline PBMC proliferation indicating a degree of innate immune privilege. Limbal CSC could be differentiated into KDCs that expressed Keratocan, Lumican, and ALDH1A3 and downregulated Pax6 and N-cadherin. In conclusion, canine CSCs have multipotent MSC properties similarly described in humans and could serve as a source of cells for cell therapy and studying corneal diseases.


Subject(s)
Cornea/cytology , Mesenchymal Stem Cells/cytology , Stromal Cells/cytology , Adipocytes/cytology , Adipocytes/metabolism , Animals , Biomarkers/metabolism , Cell Culture Techniques , Cell Differentiation/physiology , Cell Proliferation/physiology , Cell- and Tissue-Based Therapy/methods , Cells, Cultured , Chondrocytes/cytology , Chondrocytes/metabolism , Cornea/metabolism , Dogs , Female , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/metabolism , Male , Mesenchymal Stem Cells/metabolism , Stromal Cells/metabolism
3.
Stem Cells Dev ; 28(21): 1413-1423, 2019 11 01.
Article in English | MEDLINE | ID: mdl-31507234

ABSTRACT

In horses and humans, tendon injuries are a significant problem. Not only can they occur in both athletes and nonathletes, they require lengthy periods of recuperation and undergo poor natural regeneration, which leads to high reinjury rates. Embryonic stem cells (ESCs) may provide a renewable source of allogeneic cells to use in clinical applications to aid tissue regeneration. Equine ESCs can undergo tenocyte differentiation in vivo and in vitro, but the immune properties of tenocytes isolated from either ESCs or tissues have not previously been characterized. Here, we demonstrate that equine tenocytes derived from fetal and adult tendon tissue and ESCs express robust levels of major histocompatibility complex (MHC) I but no MHC II in response to inflammatory cytokine interferon gamma (IFNγ). However, MHC expression does not affect their allorecognition by peripheral blood mononuclear cells in vitro. Adult and fetal tenocytes remain immune privileged and strongly immune suppressive in both the presence and absence of exogenously applied IFNγ. In contrast, ESC-derived tenocytes are immune privileged even in the presence of IFNγ, but they are only weakly immune suppressive in the presence but not in the absence of exogenously applied IFNγ. This is despite ESC-tenocytes expressing a number of genes involved in immune modulation at significantly higher levels than those expressed by adult and fetal tenocytes when in standard, nonstimulated monolayer culture. Together, this work suggests that, similar to other fibroblasts, tenocytes have immune modulatory properties, and that culture-expanded tenocytes derived from primary tissues or ESCs may be safe to use in clinical transplantations to injured tendons of unrelated animals.


Subject(s)
Cell- and Tissue-Based Therapy/methods , Embryonic Stem Cells/cytology , Immunomodulation/immunology , Interferon-gamma/pharmacology , Tendon Injuries/therapy , Tenocytes/transplantation , Animals , Cell Differentiation/physiology , Cell Line , Guided Tissue Regeneration/methods , Histocompatibility Antigens Class I/immunology , Horses , Humans , Interferon-gamma/metabolism , Leukocytes, Mononuclear/immunology , Membrane Proteins/metabolism , Tendons/cytology , Tenocytes/cytology , Tenocytes/immunology
4.
Sci Rep ; 9(1): 2755, 2019 02 26.
Article in English | MEDLINE | ID: mdl-30808942

ABSTRACT

Interleukin 1ß (IL-1ß) is upregulated following tendon injury. Here we demonstrate that in adult and fetal tenocytes IL-1ß increases the expression of matrix metalloproteinases, tenascin-C and Sox9 and decreases the expression of scleraxis and cartilage oligomeric matrix protein. When cultured in 3-dimensional collagen gels adult and fetal tenocytes exposed to IL-1ß have reduced contraction ability and generate tendon-like constructs with a lower storage modulus. In contrast, equine embryonic stem cell (ESC) derived tenocytes exposed to IL-1ß exhibit no changes in gene expression and generate identical tendon-like constructs. We propose that ESC-derived tenocytes do not respond to IL-1ß due to their low expression of interleukin 1 (IL-1) receptor 1 and high expression of the decoy receptor IL-1 receptor 2 and IL-1 receptor antagonist protein (IL1Ra). This may make ESC-derived tenocytes an advantageous source of cells for tissue regeneration and allow the development of novel pharmaceutical interventions to protect endogenous cells from inflammation.


Subject(s)
Gene Expression/drug effects , Interleukin-1beta/pharmacology , Animals , Basic Helix-Loop-Helix Transcription Factors/genetics , Basic Helix-Loop-Helix Transcription Factors/metabolism , Cell Culture Techniques , Cells, Cultured , Collagen/metabolism , Embryonic Stem Cells/cytology , Embryonic Stem Cells/metabolism , Fetus/cytology , Horses , Interleukin 1 Receptor Antagonist Protein/genetics , Interleukin 1 Receptor Antagonist Protein/pharmacology , Matrix Metalloproteinases/genetics , Matrix Metalloproteinases/metabolism , Signal Transduction/drug effects , Tenascin/genetics , Tenascin/metabolism , Tenocytes/cytology , Tenocytes/drug effects , Tenocytes/metabolism
5.
Biol Open ; 7(5)2018 May 10.
Article in English | MEDLINE | ID: mdl-29685993

ABSTRACT

Bone fractures occur in horses following traumatic and non-traumatic (bone overloading) events. They can be difficult to treat due to the need for the horse to bear weight on all legs during the healing period. Regenerative medicine to improve fracture union and recovery could significantly improve horse welfare. Equine induced pluripotent stem cells (iPSCs) have previously been derived. Here we show that equine iPSCs cultured for 21 days in osteogenic induction media on an OsteoAssay surface upregulate the expression of osteoblast associated genes and proteins, including COL1A1, SPARC, SPP1, IBSP, RUNX2 and BGALP We also demonstrate that iPSC-osteoblasts are able to produce a mineralised matrix with both calcium and hydroxyapatite deposition. Alkaline phosphatase activity is also significantly increased during osteoblast differentiation. Although the genetic background of the iPSC donor animal affects the level of differentiation observed after 21 days of differentiation, less variation between lines of iPSCs derived from the same horse was observed. The successful, direct, differentiation of equine iPSCs into osteoblasts may provide a source of cells for future regenerative medicine strategies to improve fracture repair in horses undergoing surgery. iPSC-derived osteoblasts will also provide a potential tool to study equine bone development and disease.

SELECTION OF CITATIONS
SEARCH DETAIL
...